Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus

@inproceedings{Ven2015MinimumTP,
  title={Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus},
  author={Nikolien van de Ven and Joe Fortunak and Bryony Simmons and Nathan Ford and Graham S Cooke and Saye Khoo and Andrew Hill},
  booktitle={Hepatology},
  year={2015}
}
UNLABELLED Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory diagnostics are very low. This analysis aimed to estimate minimum costs of DAA treatment and associated diagnostic monitoring. Clinical trials of HCV DAAs were reviewed to identify combinations with consistently high rates of sustained… CONTINUE READING